MedTech Advances, Regulatory Shifts & Global Expansion

Ciao peers, colleagues, family, and friends! Welcome to another edition of my monthly roundup of interesting industry trends and insights. If you’re a first-time subscriber, welcome! This month we’ll be exploring interesting new developments in the world of MedTech Research and the new FDA Legislature for cosmetics companies, as well as great news from PQE Group!

MedTech News: New detection methods in mitochondrial dysfunction has led scientists at the University of California, San Diego, to develop a screening method for people with refractory (non-treatable) depression. The research this new study has uncovered may lead to an ability to one day actively monitor levels of mitochondrial dysfunction in individuals using wearables to determine the difference between someone who is depressed (like after a breakup) and someone who is suicidal. Medications that help adjust mitochondrial function or otherwise mimic ATP might also someday make a difference in the lives of millions of sufferers of depression worldwide.??

FDA Pharma Regulations: In December new FDA regulation went into effect for cosmetics companies. The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides stricter guidance around the following, “Adverse Event,” “Facility,” and, “Responsible Person.” If you are a cosmetics company struggling to clear these new regulatory hurdles, or didn’t know about them in the first place, PQE Group can assist you in getting things on track. Compliance is a confusing, difficult, and often tedious process that founders and business owners should not have to concern themselves with.?

In my opinion, the best run businesses are quietly compliant. They adhere to the latest in regulation in a sense that their methods to stay compliant do not interrupt the daily flow of life inside each business.?

PQE Group opens Singapore Office: I’m very excited to announce the opening of our new Singapore office, which marks PQE Group’s first steps into Southeast Asia. Singapore’s reputation as a thriving hub for technology companies and startups opens the door to endless opportunities for PQE Group. According to analysis by Google Trends, Asia-Pacific takes the crown for FemTech growth, with a projected Compound Annual Growth Rate (CAGR) of 14.42% from 2024 to 2029. Factors driving this growth include:

• Increasing disposable income and smartphone penetration.
• Growing awareness and openness towards women's health issues.
• Rising prevalence of chronic diseases among women.
• Government initiatives supporting healthcare innovation.

Analysis also notes how the mental health sub-sector of Femtech is booming, with a CAGR of 22.3% predicted for 2023-2028. This surge is fueled by:

• Rising awareness of mental health issues among women.
• Increased accessibility of online therapy and mental health resources.
• De-stigmatization of mental health discussions.

With both of those factors in play, PQE Group’s foray into the ASEAN trading bloc may come at just the right time as new apps, devices, and startups focused on women’s health and wellbeing continue to accelerate at unprecedented speed.?

PQE Group surpasses €100,000,000 in revenue for the first time: In 2023 we saw 10% growth and an upwardly revised income exceeding 100M Euro as well as the inauguration of new offices in Canada, Saudi Arabia, Ireland and Singapore, bringing the total to 46 offices and 26 legal entities worldwide.?

At a time when many companies grapple with geopolitical challenges, crises, and inflation rates, PQE Group stands out not only for its resilience but for its ability to thrive in uncertain times, showcasing positive growth across all financial indicators.?

This success is rooted in meticulous planning, strategic investments in cutting-edge technologies, and a corporate culture that values agility and innovation. Everyone in the PQE Family should share in this good news, it’s your hard work that has made our incredible story of rapid growth and success possible!